The 8 analysts offering 12-month price forecasts for Haemonetics Corp have a median target of 77.50, with a high estimate of 90.00 and a low estimate of 68.00. The median estimate represents a +11.62% increase from the last price of 69.43.
The current consensus among 8 polled investment analysts is to Buy stock in Haemonetics Corp. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.61
Reporting Date Nov 10
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.